Corcept Therapeutics Incorporated's (NASDAQ:CORT) Shares May Have Run Too Fast Too Soon

NASDAQ:CORT) price-to-earnings (or "P/E") ratio of 19.1x is worth a mention when the median P/E in the United States is similar at about 19x. While this might not raise any eyebrows, if the P/E ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.” data-reactid=”28″>There wouldn’t be many who think Corcept Therapeutics Incorporated’s (NASDAQ:CORT) price-to-earnings (or “P/E”) ratio of 19.1x is worth a mention when the median P/E in the United States is similar at about 19x. While this might not raise any eyebrows, if the P/E ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.

With its earnings growth in positive territory compared to the declining earnings of most other companies, Corcept Therapeutics has been doing quite well of late. One possibility is that the P/E is moderate because investors think the company’s earnings will be less resilient moving forward. If you like the company, you’d be hoping this isn’t the case so that you could potentially pick up some stock while it’s not quite in favour.

Check out our latest analysis for Corcept Therapeutics ” data-reactid=”30″> Check out our latest analysis for Corcept Therapeutics

free report on Corcept Therapeutics.” data-reactid=”47″>If you’d like to see what analysts are forecasting going forward, you should check out our free report on Corcept Therapeutics.

What Are Growth Metrics Telling Us About The P/E?

There’s an inherent assumption that a company should be matching the market for P/E ratios like Corcept Therapeutics’ to be considered reasonable.

If we review the last year of earnings growth, the company posted a terrific increase of 46%. The latest three year period has also seen an excellent 362% overall rise in EPS, aided by its short-term performance. So we can start by confirming that the company has done a great job of growing earnings over that time.

Looking ahead now, EPS is anticipated to climb by 2.7% per annum during the coming three years according to the four analysts following the company. Meanwhile, the rest of the market is forecast to expand by 13% per year, which is noticeably more attractive.

With this information, we find it interesting that Corcept Therapeutics is trading at a fairly similar P/E to the market. It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock. These shareholders may be setting themselves up for future disappointment if the P/E falls to levels more in line with the growth outlook.

What We Can Learn From Corcept Therapeutics’ P/E?

Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.

Our examination of Corcept Therapeutics’ analyst forecasts revealed that its inferior earnings outlook isn’t impacting its P/E as much as we would have predicted. When we see a weak earnings outlook with slower than market growth, we suspect the share price is at risk of declining, sending the moderate P/E lower. This places shareholders’ investments at risk and potential investors in danger of paying an unnecessary premium.

1 warning sign for Corcept Therapeutics that you should be aware of.” data-reactid=”56″>There are also other vital risk factors to consider before investing and we’ve discovered 1 warning sign for Corcept Therapeutics that you should be aware of.

our interactive list of stocks with solid business fundamentals for some other companies you may have missed.” data-reactid=”57″>If you’re unsure about the strength of Corcept Therapeutics’ business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Get in touch with us directly. Alternatively, email [email protected].” data-reactid=”58″>This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].